Literature DB >> 2093442

Azathioprine, cyclophosphamide and chlorambucil.

R A Luqmani, R G Palmer, P A Bacon.   

Abstract

Immunosuppressive agents serve a major role in the management of once-fatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action. This is in keeping with their differing rates of action, and different indications. Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis. Cyclophosphamide has transformed the outlook of many forms of vasculitis. Chlorambucil is particularly useful in improving the prognosis for children with amyloidosis secondary to juvenile chronic arthritis. We have tried to highlight the role of these drugs in a number of rheumatic diseases. We have emphasized their clinical applications, with some laboratory evidence for their effects. The major side-effects are reviewed. Finally, we have discussed their possible mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2093442     DOI: 10.1016/s0950-3579(05)80009-3

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  5 in total

1.  "Second line" drugs for rheumatoid arthritis.

Authors:  R D Sturrock
Journal:  BMJ       Date:  1991-07-27

Review 2.  ANCA-associated vasculitis: diagnosis and treatment in the elderly.

Authors:  R Parry; S Sherwin; V Fletcher; P Medcalf
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

Review 3.  Treatment of vasculitis.

Authors:  H G Taylor; A Samanta
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 4.  Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

Authors:  R Luqmani; C Gordon; P Bacon
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

5.  Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

Authors:  E M McDermott; R J Powell
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.